Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)

This study will characterize adoption, quantify impact, and determine cost-effectiveness of long-acting injectable HIV preexposure prophylaxis (LAI PrEP) to inform implementation strategies. We will evaluate implementation and impact of LAI PrEP in geographically and racially diverse areas of the U.S. with high HIV incidence and will include members of 3 regions of Kaiser Permanente: Northern California, Mid-Atlantic, and Georgia. Specific Aims include: 1) characterizing adoption and clinical outcomes of LAI PrEP in clinical practice; 2) quantifying the impact of LAI PrEP on HIV incidence and drug resistance; and 3) determining the cost-effectiveness of LAI vs. oral PrEP. The expected outcome of this study is actionable evidence on the adoption and projected impact of LAI PrEP in the first years of its availability, informing long-term implementation strategies for PrEP scale-up in the U.S.

0